|  |  |
| --- | --- |
| **Domain:** | Alcohol, Tobacco and Other Substances |
| **Measure:** | Substances - Lifetime Use |
| **Definition:** | Question asking the respondent if s/he has ever used a drug during his or her entire life. |
| **Purpose:** | This measure can be used to assess the participant's lifetime use of any drug. The question is often used as a prelude to more detailed questions about substance use to screen out individuals who have ever used these substances. |
| **Essential PhenX Measures:** | Current Age |
| **Related PhenX Measures:** | Substances - 30-Day Frequency Substances - Age of First Use Substance Abuse and Dependence - Past Year |
| **Collections:** | Other Substance Use Core: Tier 1 Mental Health Research Core: Tier 2 Sickle Cell Disease: Core Tier 2 SCD Neurology, Quality of Life, and Health Services Additional Relevant Measures |
| **Keywords:** | drugs, substance use, illicit substances, cannabis, marijuana, THC, hashish, LSD, acid, PCP, angel dust, phencyclidine, peyote, mescaline, psilocybin, ecstasy, MDMA, sedative, tranquilizer, anti-anxiety drug, painkiller, stimulant, prescription drug, cocaine, crack cocaine, hallucinogen, inhalent, solvent, heroin, substance abuse, sleeping pills, barbiturates, Seconal, Quaaludes, or Chloral Hydrate, Valium, Librium, muscle relaxants, Zanax, Codeine, Darvon, Percodan, Dilaudid, Demerol, Preludin, Benzedrine, Methadrine, uppers, speed, amyl nitrate, nitrous oxide, glue, tolune, gasoline, Alcohol Use Disorder and Associated Disabilities Interview Schedule, AUDADIS, National Institute on Alcohol Abuse and Alcoholism National Epidemiologic Survey on Alcohol and Related Conditions, NIAAA, NESARC, Diagnostic and Statistical Manual of Mental Disorders |

|  |  |
| --- | --- |
| **Protocol Release Date:** | February 6, 2009 |
| **PhenX Protocol Name:** | Substances - Lifetime Use |
| **Protocol Name from Source:** | The Expert Review Panel has not reviewed this measure yet. |
| **Description:** | Measurement of respondent's lifetime use of illicit and prescribed substances. |
| **Specific Instructions:** | Respondents will answer yes or no to the following list of drugs. If he or she indicates that he or she has used a specific drug (even experimentally), the interviewer will query for the specific drug(s) used. Note that the protocol specified below has been adapted so that the names of the drug categories are listed as noted in Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) survey (see Source below). In Wave 1, each drug category was phonetically spelled out for the interviewer. |
| **Protocol:** | *The Working Group acknowledges that the following questions may gather sensitive information relating to the use of substances and/or illegal conduct. If the information is released it might be damaging to an individual's employability, lead to social stigmatization, or other consequences.*  *For information on obtaining a Certificate of Confidentiality, which helps researchers protect the privacy of human research participants, please go to the National Human Genome Research Institute's Institutional Review Board website.*  *The following questions are asked of the respondent. First read the introductory paragraph to the respondent. Show the respondent the flashcard (provided below) and read to the respondent the list of drug categories (items 1-10). If the respondent answers "Yes" to any drug category, ask* ***Which ones****? Record the specific drug(s) used.*  Now I'd like to ask you about your experiences with medicines and other kinds of drugs that you may have used ON YOUR OWN - that is, either WITHOUT a doctor's prescription *(PAUSE)*; in GREATER amounts, MORE OFTEN, or LONGER than prescribed *(PAUSE)*; or for a reason other than a doctor said you should use them. People use these medicines and drugs ON THEIR OWN to feel more alert, to relax or quiet their nerves, to feel better, to enjoy themselves, or to get high or just to see how they would work.  Have you EVER used any of these medicines or drugs?  [] 1 Sedatives, for example, sleeping pills, barbiturates, Seconal®, Quaaludes, or Chloral Hydrate - *Specify ↓*  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  [] 2 Tranquilizers or anti-anxiety drugs, for example, Valium®, Librium®, muscle relaxants, or Zanax® - *Specify ↓*  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  [] 3 Painkillers, for example, Codeine, Darvon®, Percodan®, OxyContin®, Dilaudid®, Demerol®, Celebrex®, or Vioxx® - *Specify ↓*  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  [] 4 Stimulants, for example, Preludin®, Benzedrine®, Methedrine®, Ritalin®, uppers, or speed - *Specify ↓*  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  [] 5 Marijuana, hash, THC, or grass - *Specify ↓*  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  [] 6 Cocaine or crack - *Specify ↓*  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  [] 7 Hallucinogens, for example, Ecstasy/MDMA, LSD, mescaline, psilocybin, PCP, angel dust, or peyote - *Specify ↓*  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  [] 8 Inhalants or solvents, for example, amyl nitrite, nitrous oxide, glue, toluene or gasoline - *Specify ↓*  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  [] 9 Heroin  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  [] 10 Any OTHER medicines, or drugs, or substances, for example, methadone, Elavil®, steroids, Thorazine®, or Haldol®? - (*SELECT MOST FREQUENTLY USED OTHER DRUG*)  \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  *The following supplemental flashcard has been revised from the original to reflect the ten drug categories listed in the Alcohol Use Disorder and Associated Disabilities Interview Schedule Fourth Edition Version (AUDADIS-IV) instrument.\**  **Flashcard**  **\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**  **TYPES OF MEDICINES/DRUGS**  **1. Sedatives**, for example, sleeping pills, barbiturates, Seconal®, Quaaludes®, or Chloral Hydrate®  **2. Tranquilizers or anti-anxiety drugs**, for example, Valium®, Librium®, muscle relaxants, or Zanax®  **3. Painkillers**, for example, Codeine, Darvon®, Percodan®, Dilaudid®, or Demerol®  **4. Stimulants**, for example, Preludin®, Benzedrine®, Methadrine®, uppers, or speed  **5. Marijuana, hash, THC, or grass**  **6. Cocaine or crack**  **7. Hallucinogens**, for example, Ecstasy, LSD, mescaline, psilocybin, PCP, angel dust, or peyote  **8. Inhalants or Solvents**, for example, amyl nitrate, nitrous oxide, glue, tolune, or gasoline  **9. Heroin**  **10. Any OTHER medicines, drugs, or substances**, for example, Methadone®, Elavi®l, steroids, Thorazine®, or Haldol®  \* The original Wave 1 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) instrument had ten categories for the lifetime substance use question: Categories 1-8 listed above, along with two additional slots where the respondent could name one of the "other" drugs (including heroin). While editing the data from the Wave 1 responses, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) determined a single category for heroin would be appropriate, leaving only one field for coding "other" drugs. The Alcohol Use Disorder and Associated Disabilities Interview Schedule Fourth Edition Version (AUDADIS - IV) was modified to create a separate category 9 for heroin and a category 10 for other drugs and edited the AUDADIS questionnaire to reflect this change.  *Seconal® a registered trademark, Eli Lilly and Company; Valium® a registered trademark, Hoffman LaRoche Inc.; Librium® a registered trademark, Valeant Pharmaceuticals International; Zanax® a registered trademark, UpJohn Company; Darvon® a registered trademark, Eli Lilly and Company; Percodan® a registered trademark, ENDO Pharmaceuticals, Inc.; OxyContin® a registered trademark, Purdue Pharma, LP; Dilaudid® a registered trademark, Purdue Pharma, LP; Demerol® a registered trademark, Sanofi-Aventis Group; Celebrex® a registered trademark, G.D. Searle & Co.; Vioxx® a registered trademark, Merck & Co., Inc.; Preludin® a registered trademark, Boehringer-Ingelheim; Benzedrine® a registered trademark, GlaxoSmithKline; Methedrine® a registered trademark, GlaxoSmithKline; Ritalin® a registered trademark, Novartis Pharmaceuticals Corp.; Elavil® a registered trademark, Astra Zeneca Pharmaceuticals., Inc; Thorazine® a registered trademark, GlaxoSmithKline; Haldol® a registered trademark, Ortho-McNeil Pharmaceutical, Inc.* |
| **Selection Rationale:** | The protocol from the Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS) was chosen because it was used in a large epidemiological study containing adults with a wide age range and different ethnicities (Wave 1 included 43,093 Americans; in Wave 2, 34,653 members of the original cohort were reinterviewed). The measures from this survey have been validated and psychometrically tested. |
| **Source:** | National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Epidemiologic Survey on Alcohol and Related Conditions. Wave 1 (NESARC - WAVE 1). Alcohol Use Disorder and Associated Disabilities Interview Schedule - Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition Version (AUDADIS-IV), Section 3B (question 1a).  Grant, B. F., Dawson, D. A., Stinson, F. S., Chou, P. S., Kay, W., & Pickering, R. (2003). The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): Reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. *Drug and Alcohol Dependence,* *71*(1), 7-16. |
| **Life Stage:** | Adult |
| **Language of source:** | English, Available in other languages |
| **Participant:** | ≥18 years |
| **Personnel and Training Required:** | Interviewer must be trained and found competent to conduct personal interviews with individuals from the general population. The interviewer should be trained to prompt respondents further if a "don't know" response is provided. |
| **Equipment Needs:** | While the Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV) instrument was developed for administration by computer, the PhenX Working Group acknowledges that these questions can be administered in a noncomputerized format. Hasin et al. (1997) and Grant et al. (1995) used the AUDADIS in paper-and-pencil format, while Grant et al. (2003) obtained data with the computerized format. |
| **Standards:** | |  |  |  |  | | --- | --- | --- | --- | | **Standard** | **Name** | **ID** | **Source** | | Common Data Element (CDE) | Person Substance of Abuse Consumption Indicator | 2821039 | [CDE Browser](https://cdebrowser.nci.nih.gov/CDEBrowser/search?elementDetails=9&FirstTimer=0&PageId=ElementDetailsGroup&publicId=2821039&version=1.0) | | Logical Observation Identifiers Names and Codes (LOINC) | Substance - lifetime use proto | 62505-3 | [LOINC](http://s.details.loinc.org/LOINC/62505-3.html?sections=Web) | |
| **General references:** | Grant, B. F., Dawson, D. A., Stinson, F. S., Chou, P. S., Kay, W., & Pickering, R. (2003). The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): Reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. *Drug and Alcohol Dependence,* *71*(1), 7-16.  Grant, B. F., Harford, T. C., Dawson, D. A., Chou, P. S., & Pickering, R. P. (1995). The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): Reliability of alcohol and drug modules in a general population sample. *Drug and Alcohol Dependence,* *39*(1), 37-44.  Hasin, D., Carpenter, K. M., McCloud, S., Smith, M., & Grant, B. F. (1997). The alcohol use disorder and associated disabilities interview schedule (AUDADIS): Reliability of alcohol and drug modules in a clinical sample. *Drug and Alcohol Dependence,* *44*(2-3), 133-141. |
| **Mode of Administration:** | Interviewer-administered questionnaire |
| **Derived Variables:** | None |
| **Requirements:** | |  |  | | --- | --- | | **Requirement Category** | **Required** | | Major equipment | No | | Specialized training | No | | Specialized requirements for biospecimen collection | No | | Average time of greater than 15 minutes in an unaffected individual | No | |
| **Process and Review:** | The Expert Review Panel has not reviewed this measure yet. |